SAN FRANCISCO—The SELECT-ACS trial, which sought to determine the efficacy of inclacumab, suggests that the P-selectin antagonist inclacumab reduces myocardial damage after PCI in patients with NSTEMI. The trial was presented as a late-breaking clinical trial at the 62nd American College of Cardiology (ACC) scientific session.
P-selectin, a cell adhesion molecule expressed on activated endothelial cells and platelets, plays a critical role in leukocyte and platelet rolling.
About the presenter
Jean-Claude Tardif, MD, is the director of the research center and cardiologist at the Montreal Heart Institute and professor of medicine at the University of Montreal. He also is the Director of the Cardiovascular Health Network of the Quebec Health Research Fund and the Canadian Institutes of Health Research and Pfizer chair in atherosclerosis. In addition, he is the scientific director of the Montreal Heart Institute Coordinating Centre and chairman of the steering committee of the CIHR-funded Canadian Atherosclerosis Imaging Network.